Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progestins in the menopause.

R Sitruk-Ware1

  • 1Department of Endocrinology, St Antoine Hospital, Paris, France.

The Journal of Steroid Biochemistry and Molecular Biology
|July 27, 1999
PubMed
Summary

Hormone replacement therapy (HRT) with progestins offers endometrial protection. Selecting progestins without androgenic properties minimizes risks to breast tissue and cardiovascular health, enhancing HRT safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.

Andrology·2019
Same author

Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

Andrology·2018
Same author

Non-clinical studies of progesterone.

Climacteric : the journal of the International Menopause Society·2018
Same author

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Contraception·2018
Same author

Neurosteroidogenesis and progesterone anti-inflammatory/neuroprotective effects.

Journal of neuroendocrinology·2017
Same author

Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.

Andrology·2017

Area of Science:

  • Endocrinology
  • Gynecology
  • Cardiovascular Medicine

Background:

  • Progestins in hormone replacement therapy (HRT) are recognized for endometrial protection.
  • Controversy exists regarding progestin risks and benefits, particularly concerning breast tissue and cardiovascular health.
  • Progestin effects on breast cells vary by type, dose, and duration, often showing antiproliferative effects.

Purpose of the Study:

  • To evaluate the risks and benefits of progestin use in HRT.
  • To analyze the impact of different progestins on breast tissue and cardiovascular risk factors.
  • To determine optimal progestin selection for HRT to minimize adverse effects.

Main Methods:

  • Review of epidemiological studies on HRT and breast cancer risk.
  • Analysis of progestin effects on lipid profiles and vasomotion.
  • Examination of HRT impact on cardiovascular morbidity and mortality, considering progestin androgenicity.

Main Results:

  • Most studies show no difference in breast cancer risk between estrogen-only HRT and combined HRT.
  • Androgenic progestins can attenuate beneficial estrogen effects on lipids and vasomotion.
  • Epidemiological data generally do not link combined HRT with negative cardiovascular outcomes, but androgenic progestins may be detrimental in women with existing coronary heart disease (CHD).

Conclusions:

  • Progestins are crucial for endometrial protection in HRT.
  • Selecting progestins devoid of estrogenic, androgenic, or glucocorticoid activity is key to maximizing HRT benefits and minimizing risks.
  • Careful progestin selection can expand HRT use without significant drawbacks, especially in women with cardiovascular considerations.

Related Experiment Videos